Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07171619 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Phase 1 study of Healthy, sponsored by SpringWorks Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07171619 is a Phase 1 study of Healthy that is actively recruiting participants, run by SpringWorks Therapeutics. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07171619, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by SpringWorks Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
Conditions Studied
Interventions
- DRUG Nirogacestat
- DRUG Nirogacestat and Famotidine
- DRUG Nirogacestat and Rabeprazole
Study Locations (1)
Ohio
- Medpace - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07171619
The ClinicalTrials.gov registry entry for NCT07171619 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is SpringWorks Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Nirogacestat is the first listed.
NCT07171619 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07171619 about?
NCT07171619 is a clinical study titled "Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat". This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
What is the current status of trial NCT07171619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-09-09. Estimated completion is 2025-11.
What conditions does trial NCT07171619 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT07171619?
The interventions under investigation include: Nirogacestat (DRUG), Nirogacestat and Famotidine (DRUG), Nirogacestat and Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT07171619?
This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07171619 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.